Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1465568

registered interest
date	24/05/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Air Ambulance Services: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made a recent assessment of the potential merits of providing funding to regional air ambulance services in England.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	8198
answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>No recent assessment has been made. In 2019, the Department launched a three-year capital grant programme which allocated £10 million to nine air ambulance charities in England. A further £6 million was provided in 2020 in response to the COVID-19 pandemic, which was allocated to Air Ambulances UK to distribute to the 21 air ambulance charities in the United Kingdom. We continue to support a charitable model for the funding of air ambulance services. Decisions on the provision of services are made locally and maintaining a charitable model allows charities the independence to deliver specialised services tailored to the needs of patients.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 06/06/2022 09:06:40 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1378161

registered interest
date	12/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Redundancy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the (a) planned and (b) estimated percentage reduction is to (i) staff at the Medicines and Healthcare products Regulatory Agency and (ii) licensing and assessment staff from 2019 through to March 2022.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	73982
answer	answer is ministerial correction date of answer 22/11/2021 answer text <p>The transformation programme at the Medicines and Healthcare products Regulatory Agency will lead to a reduction in the workforce of approximately 20%. The current proposed structure is currently being reviewed in light of feedback following staff consultation and will be communicated to the organisation in the week commencing 22 November.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 22/11/2021 11:31:43 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1378162

registered interest
date	12/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, in the context of the reduction of Medicines and Healthcare products Regulatory Agency (MHRA) licensing assessors, what role the (a) European Medicines Agency, (b) USA's Food and Drugs Administration and (c) British standards institutions will have in approving new drug licences from 2022.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	73983
answer	answer is ministerial correction date of answer 22/11/2021 answer text <p>Following the United Kingdom’s exit from the European Union, the Medicines and Healthcare products Regulatory Agency (MHRA) has offered a range of new routes to market, including a rapid 150 day assessment procedures for new drugs and the Innovative Licensing and Access Pathway which aims to accelerate the time to market, facilitating patient access to medicines for life-threatening or seriously debilitating conditions or those where there is a significant patient or public health need. If companies already have a licence granted by the European Commission through the European Medicines Agency, they may request the MHRA to rely on the decision of the European Commission in granting an authorisation for Great Britain and the final decision to authorise is made by the MHRA. The European Commission’s authorisation is automatically valid for Northern Ireland.</p><p>The MHRA is now participating in two international work sharing collaborations, including Project Orbis, co-ordinated by the Food and Drug Administration to review and approve promising cancer treatments. However, each country remains fully independent on its final regulatory decision. Applications submitted to the MHRA within a Project Orbis procedure are national marketing authorisation applications and variations.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 22/11/2021 11:26:50 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1366427

registered interest
date	05/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Written Questions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to Question 58525 tabled on 18 October 2021, when his Department plans to respond to hon. Member for Twickenham regarding 111.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	70321
answer	answer is ministerial correction date of answer 22/11/2021 answer text <p>I refer the hon. Member to the answer of 19 November to Question <a href="https://questions-statements.parliament.uk/written-questions/detail/2021-10-18/58525" target="_blank">58525</a>.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 22/11/2021 13:44:10 answering member 4362 label Biography information for Edward Argar previous answer version 32249 answering member constituency Charnwood answering member printed Edward Argar answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1360709

registered interest
date	18/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS 111
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the (a) average call duration, (b) average waiting time and (c) the total number of calls wherein the person calling dropped the call, were to the NHS emergency advice service number 111 in (i) 2018, (ii) 2019, (iii) 2020 and (iv) 2021; what the average call duration has been over the last 12 months to 111; and how many calls to 111 were abandoned over the last 12 months.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	58525
answer	answer is ministerial correction date of answer 19/11/2021 answer text <p>The average call duration for NHS111 calls is not held centrally.</p><p>The average waiting time for NHS111 calls is only available for April – August 2021, and not for previous years. The average waiting from April to August 2021 was 271 seconds.</p><p>The total number of calls abandoned is only available for April – August 2021, which is 1,452,574. This data is not available for 2018, 2019, 2020 and current year to August, where only the number of calls abandoned after at least 30 seconds is available. This data is provided in the following table:</p><table><tbody><tr><td><p> </p></td><td><p><strong>2018</strong></p></td><td><p><strong>2019</strong></p></td><td><p><strong>2020</strong></p></td><td><p><strong>2021: </strong> <strong>January – August</strong></p></td></tr><tr><td><p><strong>Calls abandoned after at least 30 seconds</strong></p></td><td><p>708,548</p></td><td><p>661,906</p></td><td><p>2,160,595</p></td><td><p>1,266,546</p></td></tr></tbody></table><p>Source: NHS England</p><p> </p><p>The total number of calls abandoned over the last 12 months is not available.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 19/11/2021 14:30:41 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1359479

registered interest
date	15/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Miscarriage: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what support his Department provides for research into the (a) causes of and (b) treatment for miscarriage prevention.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	56560
answer	answer is ministerial correction date of answer 25/10/2021 answer text <p>The Department commissions research through the National Institute for Health Research (NIHR) which funds a range of research in maternal and neonatal health. In 2020/21, the NIHR’s programmes invested £2.8 million on research into miscarriage, including prevention. This includes a trial which aims to examine the effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding. In 2020/21 the NIHR invested £39.7 million in research on reproductive health and childbirth, which includes miscarriage research. This accounts for 5% of the NIHR’s total research budget. Additionally, the NIHR’s Policy Research Programme funds a Policy Research Unit dedicated to maternal and neonatal health and care research, which has a research theme to address pregnancy loss, and perinatal morbidity and mortality.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 56561 question first answered 25/10/2021 15:07:07 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1359480

registered interest
date	15/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Miscarriage: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the (a) total cost and (b) cost to the public purse as a proportion of his Department's research budget is of departmental research into miscarriages in the last 12 months for which figures are available.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	56561
answer	answer is ministerial correction date of answer 25/10/2021 answer text <p>The Department commissions research through the National Institute for Health Research (NIHR) which funds a range of research in maternal and neonatal health. In 2020/21, the NIHR’s programmes invested £2.8 million on research into miscarriage, including prevention. This includes a trial which aims to examine the effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding. In 2020/21 the NIHR invested £39.7 million in research on reproductive health and childbirth, which includes miscarriage research. This accounts for 5% of the NIHR’s total research budget. Additionally, the NIHR’s Policy Research Programme funds a Policy Research Unit dedicated to maternal and neonatal health and care research, which has a research theme to address pregnancy loss, and perinatal morbidity and mortality.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 56560 question first answered 25/10/2021 15:07:07 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1359810

registered interest
date	15/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the cost to the public purse is of (a) research and (b) trials in respect of pulmonary fibrosis.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	57382
answer	answer is ministerial correction date of answer 28/10/2021 answer text <p>The National Institute for Health Research (NIHR) is the nation’s largest funder of health and social care research. In 2020/21 it awarded £696,932 for research into pulmonary fibrosis. Currently, the NIHR supports 122 studies into pulmonary fibrosis with two current COVID-19 related studies. One study is evaluating the safety and efficacy of Deupirfenidone in post-acute COVID-19 respiratory disease. The second is evaluating the efficacy and safety of Remdesivir treatment of COVID-19 in an outpatient setting.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 57383 question first answered 28/10/2021 13:24:09 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1359811

registered interest
date	15/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has undertaken (a) research and (b) trials to investigate whether treatments for covid-19 can be used for pulmonary fibrosis.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	57383
answer	answer is ministerial correction date of answer 28/10/2021 answer text <p>The National Institute for Health Research (NIHR) is the nation’s largest funder of health and social care research. In 2020/21 it awarded £696,932 for research into pulmonary fibrosis. Currently, the NIHR supports 122 studies into pulmonary fibrosis with two current COVID-19 related studies. One study is evaluating the safety and efficacy of Deupirfenidone in post-acute COVID-19 respiratory disease. The second is evaluating the efficacy and safety of Remdesivir treatment of COVID-19 in an outpatient setting.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 57382 question first answered 28/10/2021 13:24:09 answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson

1348009

registered interest
date	19/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Earwax: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of providing ear wax removal procedures on the NHS for (a) pensioners and (b) people on low incomes.
tabling member constituency	Twickenham
tabling member printed	Munira Wilson
uin	35901
answer	answer is ministerial correction date of answer 29/07/2021 answer text <p>NHS England and NHS Improvement recognise manual ear syringing is no longer advised by the National Institute for Health and Care Excellence due to risks associated, such as trauma to their ear drum or infection. General practitioner (GP) practices are increasingly recommending self-care methods as the primary means to support the safe removal of ear wax.</p><p>However, if a GP practice considers removal clinically necessary, the procedure should either be undertaken at the practice or the patient should be referred to an appropriate service depending on the arrangements in place in the local area, including for pensioners and those on low incomes. Local commissioners are responsible for meeting the health needs of their local population and should continue to ensure there is appropriate access to ear wax services.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 29/07/2021 11:22:06 answering member 4362 label Biography information for Edward Argar previous answer version 16530 answering member constituency Charnwood answering member printed Edward Argar answering member 4362 label Biography information for Edward Argar
tabling member	4776 label Biography information for Munira Wilson